Results 11 to 20 of about 13,488 (162)
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types [PDF]
Annals of Oncology, 2018 We hypothesized that the abundance of PD1 mRNA in tumor samples might explain the differences in overall response rates (ORR) observed following anti-PD1 monotherapy across cancer types.
L Pare +2 more
exaly +3 more sources
Histological diversity of anti-PD1-induced colitis [PDF]
, 2022 Aim. Histological data on anti-PD1-associated colitis are limited, while the colitis subtypes are still not clearly defined and different terms are being used. The aim of the study was to explore the histopathology of anti-PD1-induced colitis.
Bamias, Giorgos, +7 more
core +2 more sources
Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients. [PDF]
, 2022 Antibody-mediated cancer immunotherapy targets inhibitory surface molecules, such as PD1, PD-L1, and CTLA-4, aiming to re-invigorate dysfunctional T cells.
Müller, Stefan +16 more
core +1 more source
De ideologische positie van Algemeen Nederlands in Vlaanderen
Taal en Tongval: Language Variation in the Low Countries, 2015 The ideological position of Standard Dutch in Flanders: the standard language ideology under pressure? In this paper, the results of a perception study in Flanders are reported. 80 informants were subjected to a qualitative interview, to gain insight in
Chloé Lybaert
doaj +1 more source
Abstract PD1-01: The Impact of Structural Racism on Breast Cancer Stage at Presentation
, 2023 Background: Despite advances in diagnosis and treatment, racial and economic disparities in breast cancer-specific survival persist and this is exacerbated by later stage at presentation.
Hernandez, Alexandra +5 more
core +1 more source
The activation of T cells is typically accompanied by inhibitory mechanisms within which the programmed cell death (PD1) receptor stands out. Upon binding the ligands PDL1 and PDL2, PD1 drives T cells to an unresponsive state called exhaustion ...
Luis F. Ponce (2795155) +3 more
core +4 more sources
A triclinic polymorph of bis-(μ-di-tert-butyl-phosphanido)bis-[(di-tert-butyl-phosphane)palladium(I)] [PDF]
, 2012 A new polymorph of the title compound, [Pd2(C8H18P)2(C8H19P)2], has been found. It belongs to the triclinic P-1 space group, whereas the known form [Leoni, Sommovigo, Pasquali, Sabatino & Braga (1992 [triangle]), J. Organomet. Chem.
Lerner, Hans-Wolfram +5 more
core +1 more source
PD1 signal transduction pathways in T cells [PDF]
, 2017 The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low ...
Arasanz, H +13 more
core +1 more source
mprzedborski/ex-vivo-PD1-blockade:
, 2021 This is the code for running simulations for the manuscript "Integrating an ex vivo human tumor model with systems biology for the study of PD-1 blockade response dynamics in head and neck squamous cell carcinoma (HNSCC)", authored by: Munisha Smalley ...
mprzedborski
core +1 more source
cis-Dichloridobis(dimethoxyphenylphosphine)palladium(II)
, 2010 The title compound, [PdCl2(C8H11O2P)(2)], has a comparable structure to those of related palladium dichloride complexes containing trimethyl phosphinite and methyl diphenyl phosphinite.
Woollins, J. Derek +5 more
core +1 more source